Payment overview · 2025
General Payments
$251.49
12 reported records · 8 companies
Healthcare provider profile · identity verified
Raymond William Deen, DO
Allopathic & Osteopathic Physicians|Family Medicine · MILLEDGEVILLE, GA · NPI 1659719722
Verified facts
What the public records show
CMS Open Payments records show Raymond William Deen, DO received $251.49 in general payments during 2025 across 12 reported records.
Corcept Therapeutics accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.80 | 19.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.79 | 15.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $37.39 | 14.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.93 | 11.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.48 | 11.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.75 | 9.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.60 | 9.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.75 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.49 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.80 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $37.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 295 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 76 |
| Omeprazole | Omeprazole | 260 | 79 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 37 |
| Alprazolam | Alprazolam | 232 | 34 |
| Gabapentin | Gabapentin | 186 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 55 |
| Losartan Potassium | Losartan Potassium | 171 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 47 |
| Lisinopril | Lisinopril | 146 | 45 |
| Eliquis | Apixaban | 141 | 27 |
| Sertraline Hcl | Sertraline Hcl | 139 | 31 |
| Ozempic | Semaglutide | 136 | 25 |
| Furosemide | Furosemide | 135 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 125 | 17 |
| Tramadol Hcl | Tramadol Hcl | 121 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 42 |
| Montelukast Sodium | Montelukast Sodium | 107 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 28 |
| Mounjaro | Tirzepatide | 88 | 11 |
| Famotidine | Famotidine | 83 | 32 |
| Meloxicam | Meloxicam | 82 | 23 |
| Carvedilol | Carvedilol | 81 | 23 |
| Azithromycin | Azithromycin | 79 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 21 |
| Allopurinol | Allopurinol | 76 | 19 |
| Glipizide | Glipizide | 76 | 20 |
| Trazodone Hcl | Trazodone Hcl | 76 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Pregabalin | Pregabalin | 70 | 13 |
| Diazepam | Diazepam | 65 | 11 |
| Promethazine Hcl | Promethazine Hcl | 65 | suppressed |
| Simvastatin | Simvastatin | 63 | 18 |
| Prednisone | Prednisone | 62 | 40 |
| Celecoxib | Celecoxib | 59 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 20 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 19 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Sucralfate | Sucralfate | 43 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 35 | 33 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 16 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 28 | 19 |
| Colchicine | Colchicine | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Atenolol | Atenolol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.49 · 12 records | Corcept Therapeutics | AIRSUPRA, Cologuard Collection Kit, Fluad, Flucelvax, Korlym, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error